These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26090718)

  • 1. Opportunities for vaccine research in Europe.
    Gancberg D; Hoeveler A; Martini A; Draghia-Akli R
    Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718
    [No Abstract]   [Full Text] [Related]  

  • 2. Roadmap for the establishment of a European vaccine R&D infrastructure.
    Leroy O; Geels M; Korejwo J; Dodet B; Imbault N; Jungbluth S
    Vaccine; 2014 Dec; 32(51):7021-7024. PubMed ID: 25148773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infectious disease research investments: systematic analysis of immunology and vaccine research funding in the UK.
    Fitchett JR; Head MG; Atun R
    Vaccine; 2013 Dec; 31(50):5930-3. PubMed ID: 24176489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for epidemic infections and the role of CEPI.
    Plotkin SA
    Hum Vaccin Immunother; 2017 Dec; 13(12):2755-2762. PubMed ID: 28375764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 6. Whither vaccines?
    Rodrigues CMC; Pinto MV; Sadarangani M; Plotkin SA
    J Infect; 2017 Jun; 74 Suppl 1():S2-S9. PubMed ID: 28646957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B; Neil G; Cutcher-Gershenfeld J
    Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative decline in funding of European Commission malaria vaccine projects: what next for the European scientists working in this field?
    Thøgersen RL; Holder AA; Hill AV; Arnot DE; Imoukhuede EB; Leroy O
    Malar J; 2011 Sep; 10():255. PubMed ID: 21880156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Funding: Donor drugs.
    Willyard C
    Nature; 2016 May; 533(7601):S43-5. PubMed ID: 27144609
    [No Abstract]   [Full Text] [Related]  

  • 10. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 11. Economics and financing of vaccines for diarrheal diseases.
    Bartsch SM; Lee BY
    Hum Vaccin Immunother; 2014; 10(6):1568-81. PubMed ID: 24755623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Needs for more R&D in the field of rare diseases].
    Tiennot-Herment L
    Med Sci (Paris); 2018 May; 34 Hors série n°1():48-49. PubMed ID: 29911563
    [No Abstract]   [Full Text] [Related]  

  • 13. Bank tests drug development waters.
    Mullard A
    Nat Rev Drug Discov; 2014 Sep; 13(9):643-4. PubMed ID: 25176422
    [No Abstract]   [Full Text] [Related]  

  • 14. Can emerging drug classes improve R&D productivity?
    Meier C; Cairns-Smith S; Schulze U
    Drug Discov Today; 2013 Jul; 18(13-14):607-9. PubMed ID: 23702084
    [No Abstract]   [Full Text] [Related]  

  • 15. US drug manufacturers set up joint testing group.
    Davies E
    BMJ; 2012 Sep; 345():e6394. PubMed ID: 23002149
    [No Abstract]   [Full Text] [Related]  

  • 16. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 17. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 18. Scientific challenges and opportunities in developing novel vaccines for the emerging and developing markets: New Technologies in Emerging Markets, October 16th-18th 2012, World Vaccine Congress, Lyon.
    Kochhar S
    Hum Vaccin Immunother; 2013 Apr; 9(4):928-31. PubMed ID: 23322007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating the cons of consolidation.
    Nat Rev Drug Discov; 2009 Mar; 8(3):177. PubMed ID: 19263592
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.
    Rerks-Ngarm S; Pitisuttithum P; Ganguly N; Zhang L; Tamashiro H; Cooper DA; Vun MC; Bela B; Ditangco R; Van Kinh N; Bernstein A; Osmanov S; Mathieson B; Kent SJ; Shao Y
    Curr Opin HIV AIDS; 2010 Sep; 5(5):435-52. PubMed ID: 20978386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.